 |
市场调查报告书
商品编码
1628090
2025 - 2034 年水产养殖疫苗市场机会、成长动力、产业趋势分析与预测Aquaculture Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年，全球水产养殖疫苗市场价值为 4.074 亿美元，预计 2025 年至 2034 年复合年增长率为 8%。 全球海鲜需求的增加和可持续水产养殖实践的推动推动了这一增长。
为了满足饮食需求而扩大养鱼业，凸显了疾病爆发等挑战，这可能会严重影响获利能力和生产力。疫苗接种已成为预防感染、减少对抗生素的依赖和最大程度减少损失的重要工具。各国政府和监管机构正在积极推动疫苗接种计划，以提高鱼类健康和福利，进一步推动市场成长。重组 DNA 和次单位疫苗等疫苗开发技术的进步正在提高疫苗的功效和安全性，支持市场扩张。此外，发展中地区对水产养殖基础设施的投资不断增加，也为疫苗製造商创造了新的机会。
水产养殖疫苗是用来预防和控制养殖水生物种疾病的生物製剂。这些疫苗可促进动物健康，提高生产效率，并透过减少抗生素使用来支持永续实践。
| 市场范围 | |
|---|---|
| 开始年份 | 2024年 |
| 预测年份 | 2025-2034 |
| 起始值 | 4.074 亿美元 |
| 预测值 | 8.628 亿美元 |
| 复合年增长率 | 8% |
市场依疫苗类型分为灭活疫苗、减毒活疫苗、次单位疫苗等。 2024年，灭活疫苗占据最大的市场份额，价值3.026亿美元。这些疫苗因其安全性、持久免疫力和成本效益而备受青睐。它们能够在没有环境风险的情况下保护鱼类族群，这使其成为水产养殖疾病管理的重要组成部分。
依给药途径分，市面上有註射疫苗、浸泡疫苗、喷雾疫苗和口服疫苗。 2024年註射疫苗引领市场，占60.8%的份额。它们在直接传递抗原以刺激免疫反应方面的有效性使其成为水产养殖中控制细菌和病毒性疾病的流行选择。
根据应用情况，细菌疫苗领域在 2024 年占据主导地位，预计到 2034 年将达到 4.304 亿美元。
由于其商业重要性和易受疾病影响，鲑鱼市场预计将以 8.1% 的复合年增长率成长。对鱼蛋白的需求不断增长和可持续实践进一步支持了疫苗的采用。
欧洲在水产养殖疫苗市场上处于领先地位，水产养殖业实力雄厚的国家做出了巨大贡献。该地区对鱼类健康和福祉的关注继续推动对疫苗的需求。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 细菌和病毒感染的盛行率激增
- 提高全球水产养殖产量
- 新型水产养殖疫苗的开发与上市
- 水产养殖疫苗的采用率超过抗生素
- 产业陷阱与挑战
- 疫苗审批严格监管政策
- 复杂的疫苗开发程序
- 成长动力
- 成长潜力分析
- 监管环境
- 管道分析
- 未来市场趋势
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按疫苗类型，2021 - 2034 年
- 主要趋势
- 灭活疫苗
- 减毒活疫苗
- 亚单位疫苗
- 其他疫苗类型
第 6 章：市场估计与预测：按管理途径，2021 年至 2034 年
- 主要趋势
- 注射疫苗
- 浸泡和喷淋
- 口服疫苗
第 7 章：市场估计与预测：按应用分类，2021 - 2034 年
- 主要趋势
- 细菌
- 病毒性的
- 寄生
- 组合
第 8 章：市场估计与预测：按物种，2021 - 2034 年
- 主要趋势
- 鲑鱼
- 鳟鱼
- 罗非鱼
- 鲈鱼
- 鲷鱼
- 大菱鲆
- 鲤鱼
- 其他物种
第 9 章：市场估计与预测：按地区划分，2021 - 2034 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 挪威
- 爱尔兰
- 土耳其
- 丹麦
- 亚太地区
- 中国
- 印度
- 印尼
- 菲律宾
- 泰国
- 越南
- 澳洲
- 纽西兰
- 拉丁美洲
- 巴西
- 墨西哥
- 智利
- 中东和非洲
- 伊朗
- 埃及
第 10 章：公司简介
- CIBA
- HIPRA
- Kyoto Biken Laboratories
- Kemin Industries
- Kyoritsuseiyaku Corporation
- Merck Animal Health (Merck & Co.)
- Nisseiken
- Phibro Animal Health Corporation
- Tecnovax
- Virbac
- Veterquimica
- Vaxxinova International
- Zoetis
The Global Aquaculture Vaccines Market was valued at USD 407.4 million in 2024 and is projected to grow at a CAGR of 8% from 2025 to 2034. This growth is fueled by increasing seafood demand worldwide and the push for sustainable aquaculture practices.
The expansion of fish farming to meet dietary needs has highlighted challenges like disease outbreaks, which can significantly impact profitability and productivity. Vaccination has become an essential tool to prevent infections, reduce dependency on antibiotics, and minimize losses. Governments and regulatory bodies are actively promoting vaccination programs to enhance fish health and welfare, driving market growth further. Technological advancements in vaccine development, such as recombinant DNA and subunit vaccines, are improving vaccine efficacy and safety, supporting market expansion. Additionally, growing investments in aquaculture infrastructure in developing regions are creating new opportunities for vaccine manufacturers.
Aquaculture vaccines are biological formulations used to prevent and manage diseases in farmed aquatic species. These vaccines promote animal health, enhance production efficiency, and support sustainable practices by reducing antibiotic use.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $407.4 Million |
| Forecast Value | $862.8 Million |
| CAGR | 8% |
The market is segmented by vaccine type into inactivated, live attenuated, subunit, and others. In 2024, inactivated vaccines held the largest market share, valued at USD 302.6 million. These vaccines are highly preferred for their safety, long-lasting immunity, and cost-effectiveness. Their ability to protect fish populations without environmental risks has made them a critical component of aquaculture disease management.
By route of administration, the market includes injection, immersion, spray, and oral vaccines. Injection vaccines led the market in 2024, accounting for 60.8% of the share. Their effectiveness in directly delivering antigens to stimulate immune responses makes them a popular choice for controlling bacterial and viral diseases in aquaculture.
Based on application, the bacterial vaccine segment dominated in 2024 and is expected to reach USD 430.4 million by 2034. This growth is driven by the increasing prevalence of bacterial infections in farmed aquatic species and the development of advanced vaccines offering enhanced protection.
The salmon segment is projected to grow at a CAGR of 8.1%, driven by its commercial importance and vulnerability to diseases. Rising demand for fish protein and sustainable practices are further supporting vaccine adoption.
Europe leads the aquaculture vaccines market, with significant contributions from countries with strong aquaculture industries. The region's focus on fish health and welfare continues to drive demand for vaccines.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Surging prevalence of bacterial and viral infections
- 3.2.1.2 Increasing aquaculture production across the globe
- 3.2.1.3 Development and launch of new aquaculture vaccines
- 3.2.1.4 Rising adoption of aquaculture vaccines over antibiotics
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Stringent regulatory policies for vaccine approval
- 3.2.2.2 Complex vaccine development procedures
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Inactivated vaccine
- 5.3 Live attenuated vaccine
- 5.4 Subunit vaccine
- 5.5 Other vaccine types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Injection vaccines
- 6.3 Immersion and spray
- 6.4 Oral vaccines
Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Bacterial
- 7.3 Viral
- 7.4 Parasitic
- 7.5 Combined
Chapter 8 Market Estimates and Forecast, By Species, 2021 - 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Salmon
- 8.3 Trout
- 8.4 Tilapia
- 8.5 Seabass
- 8.6 Seabream
- 8.7 Turbot
- 8.8 Carp
- 8.9 Other species
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Norway
- 9.3.7 Ireland
- 9.3.8 Turkey
- 9.3.9 Denmark
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Indonesia
- 9.4.4 Philippines
- 9.4.5 Thailand
- 9.4.6 Vietnam
- 9.4.7 Australia
- 9.4.8 New Zealand
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Chile
- 9.6 Middle East and Africa
- 9.6.1 Iran
- 9.6.2 Egypt
Chapter 10 Company Profiles
- 10.1 CIBA
- 10.2 HIPRA
- 10.3 Kyoto Biken Laboratories
- 10.4 Kemin Industries
- 10.5 Kyoritsuseiyaku Corporation
- 10.6 Merck Animal Health (Merck & Co.)
- 10.7 Nisseiken
- 10.8 Phibro Animal Health Corporation
- 10.9 Tecnovax
- 10.10 Virbac
- 10.11 Veterquimica
- 10.12 Vaxxinova International
- 10.13 Zoetis
